Compare MUFG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MUFG | AZN |
|---|---|---|
| Founded | 1880 | 1992 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.4B | 250.7B |
| IPO Year | 2002 | 1995 |
| Metric | MUFG | AZN |
|---|---|---|
| Price | $20.97 | $185.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $23.77 | ★ $207.74 |
| AVG Volume (30 Days) | 2.7M | ★ 3.1M |
| Earning Date | 11-13-2026 | 10-30-2026 |
| Dividend Yield | 1.20% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.82 | $7.85 |
| Revenue Next Year | $13.04 | $6.36 |
| P/E Ratio | ★ $25.47 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.88 | $85.85 |
| 52 Week High | $24.26 | $212.71 |
| Indicator | MUFG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 39.36 | 67.52 |
| Support Level | $19.65 | $180.98 |
| Resistance Level | $21.18 | $193.96 |
| Average True Range (ATR) | 0.37 | 3.54 |
| MACD | 0.00 | 1.73 |
| Stochastic Oscillator | 31.61 | 74.43 |
Mitsubishi UFJ Financial Group, or MUFG, is the largest bank in Japan in terms of market capitalization and assets. It offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. MUFG also generates substantial revenue and profits outside Japan (more than 30% of its loans are outside Japan) as it provides services to Japanese corporates overseas, local consumers and businesses in Southeast Asia, and non-Japanese global corporates. MUFG also owns a 24% stake in Morgan Stanley.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.